We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Molecular Test Helps Personalize Chemotherapy for Advanced Prostate Cancer

By LabMedica International staff writers
Posted on 01 Sep 2025

Prostate cancer is the second most common cause of cancer death in men in the UK, with 55,100 new cases and 12,000 deaths expected annually. More...

Around 10,000 men in the UK are diagnosed with advanced prostate cancer each year, with most deaths occurring in patients diagnosed with advanced or metastatic disease. While treatment intensification with docetaxel alongside androgen deprivation therapy (ADT) can improve survival, response rates vary, and clinicians currently lack tools to identify who will benefit most. Now, a novel molecular test can help personalize the treatment of advanced prostate cancer and avoid unnecessary side effects of chemotherapy.

Researchers at University College London (UCL, London, UK) evaluated Veracyte’s (South San Francisco, CA, USA) Decipher Prostate Genomic Classifier test, a gene expression assay performed on routinely collected prostate tissue. The test, already widely used in the US to identify localized cancers likely to spread, is the first molecular tool with randomized trial evidence showing it can guide treatment choices for metastatic disease. The test works by profiling tumor gene expression to classify patients based on predicted chemotherapy sensitivity.

The study drew on data from 1,523 patients recruited to the STAMPEDE phase III trials who had advanced prostate cancer and began treatment with ADT. Participants received additional therapies, including abiraterone or docetaxel, and were followed for a median of 14 years. Among the 832 patients with metastatic prostate cancer, researchers linked molecular test results with long-term clinical outcomes, allowing them to assess the ability of the test to predict who benefited from docetaxel chemotherapy.

The results, published in Cell, show that among the 832 patients with metastatic prostate cancer, those with high Decipher scores had a 36% reduction in risk of death after docetaxel treatment, compared to less than 4% for those with low scores. The test consistently outperformed traditional clinical tools in identifying patients most likely to benefit. This provides the first strong evidence that a routinely available molecular test can influence chemotherapy decisions in advanced prostate cancer.

The findings highlight how gene expression tests could help avoid exposing patients unlikely to benefit to toxic side effects, while guiding others toward chemotherapy for longer survival. Additional analyses identified new molecular classifiers, including a signature linked to inactivity of the tumor suppressor gene PTEN, which predicts poorer hormone therapy response but greater chemotherapy benefit. Researchers believe these discoveries pave the way for reclassifying prostate cancer into molecular subtypes for more tailored treatments.

“The ability to personalize chemotherapy decisions based on the Decipher Prostate test will greatly enhance patient care and outcomes,” said Professor Gert Attard, lead researcher at UCL Cancer Institute and UCLH. “By identifying which patients are most likely to have a survival benefit from chemotherapy, we can avoid unnecessary side effects and develop alternative treatments for people with metastatic prostate cancer who are unlikely to benefit."

Related Links:
UCL
Veracyte


Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Pipette
Accumax Smart Series
New
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.